342 related articles for article (PubMed ID: 31010620)
41. PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.
Amoils M; Kim J; Lee C; Sunwoo JB; Colevas AD; Aasi SZ; Hollmig ST; Ma Y; Divi V
Otolaryngol Head Neck Surg; 2019 Jan; 160(1):93-99. PubMed ID: 30012051
[TBL] [Abstract][Full Text] [Related]
42. High levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) in the serum are associated with poor prognosis in HPV-negative squamous cell oropharyngeal cancer.
Carpén T; Sorsa T; Jouhi L; Tervahartiala T; Haglund C; Syrjänen S; Tarkkanen J; Mohamed H; Mäkitie A; Hagström J; Mattila PS
Cancer Immunol Immunother; 2019 Aug; 68(8):1263-1272. PubMed ID: 31240326
[TBL] [Abstract][Full Text] [Related]
43. The prognostic significance of the biomarker p16 in oropharyngeal squamous cell carcinoma.
Oguejiofor KK; Hall JS; Mani N; Douglas C; Slevin NJ; Homer J; Hall G; West CM
Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):630-8. PubMed ID: 23916365
[TBL] [Abstract][Full Text] [Related]
44. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
[TBL] [Abstract][Full Text] [Related]
45. Intratumoral HPV16-Specific T Cells Constitute a Type I-Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer.
Welters MJP; Ma W; Santegoets SJAM; Goedemans R; Ehsan I; Jordanova ES; van Ham VJ; van Unen V; Koning F; van Egmond SI; Charoentong P; Trajanoski Z; van der Velden LA; van der Burg SH
Clin Cancer Res; 2018 Feb; 24(3):634-647. PubMed ID: 29018052
[No Abstract] [Full Text] [Related]
46. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.
Zhu X; Zhang Q; Wang D; Liu C; Han B; Yang JM
Cancer Biol Ther; 2019; 20(8):1105-1112. PubMed ID: 30929569
[No Abstract] [Full Text] [Related]
47. PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.
Schneider S; Kadletz L; Wiebringhaus R; Kenner L; Selzer E; Füreder T; Rajky O; Berghoff AS; Preusser M; Heiduschka G
Histopathology; 2018 Oct; 73(4):573-584. PubMed ID: 29742291
[TBL] [Abstract][Full Text] [Related]
48. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
49. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
[TBL] [Abstract][Full Text] [Related]
50. The role of concomitant chemoradiotherapy in AJCC 7
Lu DJ; Luu M; Nguyen AT; Shiao SL; Scher K; Mita A; Anderson E; Clair JM; Ho AS; Zumsteg ZS
Oral Oncol; 2020 Nov; 110():104882. PubMed ID: 32650257
[TBL] [Abstract][Full Text] [Related]
51. PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva.
Czogalla B; Pham D; Trillsch F; Rottmann M; Gallwas J; Burges A; Mahner S; Kirchner T; Jeschke U; Mayr D; Schmoeckel E
J Cancer Res Clin Oncol; 2020 Mar; 146(3):569-577. PubMed ID: 32025868
[TBL] [Abstract][Full Text] [Related]
52. Trimodality therapy for HPV-positive oropharyngeal cancer: A population-based study: Trimodality therapy for HPV+ OPC.
Sanford NN; Hwang WL; Pike LRG; Lam AC; Royce TJ; Mahal BA
Oral Oncol; 2019 Nov; 98():28-34. PubMed ID: 31536843
[TBL] [Abstract][Full Text] [Related]
53. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
54. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
55. B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma.
Ukpo OC; Thorstad WL; Lewis JS
Head Neck Pathol; 2013 Jun; 7(2):113-21. PubMed ID: 23179191
[TBL] [Abstract][Full Text] [Related]
56. The evolving landscape of human papillomavirus-related oropharyngeal squamous cell carcinoma at a single institution in Northern Italy.
Morbini P; Alberizzi P; Ferrario G; Capello G; De Silvestri A; Pedrazzoli P; Tinelli C; Benazzo M
Acta Otorhinolaryngol Ital; 2019 Feb; 39(1):9-17. PubMed ID: 30936574
[TBL] [Abstract][Full Text] [Related]
57. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
[TBL] [Abstract][Full Text] [Related]
58. Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.
Schoenfeld JD; Gjini E; Rodig SJ; Tishler RB; Rawal B; Catalano PJ; Uppaluri R; Haddad RI; Hanna GJ; Chau NG; Rabinowits G; Lorch J; Jo VY; Krane JF; Goguen LA; Annino DJ; Abdelrahman S; Lipschitz M; Margalit DN
Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):137-145. PubMed ID: 29960819
[TBL] [Abstract][Full Text] [Related]
59. Identification of an excellent prognosis subset of human papillomavirus-associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance.
Solomon B; Young RJ; Bressel M; Cernelc J; Savas P; Liu H; Urban D; Thai A; Cooper C; Fua T; Neeson P; Loi S; Porceddu SV; Rischin D
Ann Oncol; 2019 Oct; 30(10):1638-1646. PubMed ID: 31400196
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
Vassilakopoulou M; Avgeris M; Velcheti V; Kotoula V; Rampias T; Chatzopoulos K; Perisanidis C; Kontos CK; Giotakis AI; Scorilas A; Rimm D; Sasaki C; Fountzilas G; Psyrri A
Clin Cancer Res; 2016 Feb; 22(3):704-13. PubMed ID: 26408403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]